Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.39 |
| ▸ | GSK3B | P49841 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10068456 | 0.85 | CYP3A4 (0.39) | SMN1; SMN2 | |
| SCHEMBL12984738 | 0.82 | HCAR2 (0.41) | DYRK1AGSK3BSMN1; SMN2IRAK4 | |
| SCHEMBL10037330 | 0.81 | DYRK1A (0.37) | DYRK1AGSK3BIRAK4CLK2CLK3 | |
| SCHEMBL1807234 | 0.80 | NPC1 (0.44) | DYRK1AGSK3BSMN1; SMN2SMYD3 | |
| SCHEMBL3436265 | 0.79 | HCAR2 (0.37) | DYRK1AGSK3BIRAK4 | |
| SCHEMBL3558644 | 0.79 | HCAR2 (0.37) | DYRK1AGSK3BIRAK4 | |
| SCHEMBL3436264 | 0.79 | HCAR2 (0.37) | DYRK1AGSK3BIRAK4 | |
| SCHEMBL3436267 | 0.78 | CYP3A4 (0.44) | — | |
| SCHEMBL3547638 | 0.76 | IRAK4 (0.39) | DYRK1AGSK3BSMN1; SMN2IRAK4FLT3 | |
| SCHEMBL10068465 | 0.72 | SMN1; SMN2 (0.48) | DYRK1AGSK3BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | DYRK1A 4743/4885GSK3B 4209/4885SMN1; SMN2 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.